Announcements Trials
Browse Landscape

Phase

Phase 2 44Phase 1/2 27Phase 1 24Phase 3 10Phase 2/3 4Phase 4 3Phase NA 1

Status

Recruiting 3Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 1NET 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Leukemia, Myeloid, Acute 1Gastroenteropancreatic Neuroendocrine Tumors 1

Interventions

Cisplatin 22Magnetic Resonance Spectroscopy 18Gemcitabine 14Carboplatin 14pembrolizumab 13Specimen Handling 13Paclitaxel 13Bevacizumab 11Radiotherapy 10Nivolumab 10atezolizumab 8Radiation 8Platinum 8Doxorubicin 8Docetaxel 81,2-diaminocyclohexaneplatinum II citrate 8Pemetrexed 7Drug Therapy 7Dexamethasone 7Temozolomide 6Ipilimumab 6Surgical Procedures, Operative 5Rituximab 5Radiotherapy, Intensity-Modulated 5Prednisone 5Cytarabine 5Cyclophosphamide 5Biopsy 5130-nm albumin-bound paclitaxel 5venetoclax 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Injections × 90 days × Clear all
NCT06788756 2026-04-29

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Moleculin Biotech, Inc.

Phase 2/3 Recruiting
312 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT07544056 2026-04-22

A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

BeBetter Med Inc

Phase 2/3 Not yet recruiting
446 enrolled
Breast

Triple Negative Breast Neoplasms

NCT06282588 2026-03-19

THUNDER

Cancer Research Antwerp

Phase 2/3 Recruiting
493 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡